Targeting HER3, either alone or in combination with other EGFR family members could be a promising strategy for HNSCC treatment or may pose a potential pathway to overcome HER and HER2 resistance mechanisms seen in some HNSCC cases. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.